^
Association details:
| Biomarker: | EGFR expression + TP53 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Tyrosine kinase inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Risk stratification of EGFR + lung cancer diagnosed with panel-based next-generation sequencing
Published date:
08/22/2020
Excerpt:
EGFR alterations other than exon 19 deletions (non-del19), TP53 co-mutations, and brain metastases at baseline showed independent associations of similar strengths with progression-free (PFS hazard ratios [HR] 2.1-2.3) and overall survival (OS HR 1.7-2.2), in combination defining patient subgroups with distinct outcome (EGFR+NSCLC risk Score, "ENS", p < 0.001).
DOI:
10.1016/j.lungcan.2020.08.007
